MacroGenics, Inc.
Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
Last updated:
Abstract:
CD19.times.CD3 bi-specific monovalent diabodies, and particularly, CD19.times.CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
Status:
Application
Type:
Utility
Filling date:
3 Mar 2020
Issue date:
9 Jul 2020